Roche Diagnostics Operations, Inc.

Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Other

F. Hoffmann-la Roche Ag

Herbert Andres

Johann Karl

Christian Scholz

Michael Gerg

Hartmut Duefel

Michael Schraeml

Elke Faatz

Alfred Engel

Marie-Luise Hagmann

Ursula Kunert

Hans-Peter Josel

Werner Zolg

Gabriele Pestlin

Urban Schmitt

Peter Schaarschmidt

Michael Tacke

Stefan Quint

Markus Roessler

Julia Riedlinger

Michaela Windfuhr

Frank Kowalewsky

David Casagolda Vallribera

Oliver Larbolette

Herbert Von Der Eltz

Dirk Block

Ursula-Henrike Wienhues-Thelen

Eva Hoess

Rudolf Vogel

Wolfgang Rollinger

Frederic Donie

Dorothea Sizmann

Peter Berndt

Andre Ziegler

Edelgard Anna Kaiser

Friedemann Krause

Hanno Langen

Magdalena Swiatek-de Lange

Ariuna Bazarsuren

Nina Meissler

Marion Niessner

David Morgenstern

Veit Peter Grunert

Serge Masson

Roberto Latini

Peter Kastner

Rupert Hermann

Michael Schraemi

Stefan Palme

Michael Thierolf

Markus Thomas

Simona Barlera

Ursula Garczarek

Stefan Weiser

Florian Grupp

Julia Kloeckner

André Ziegler

Edelgard Kaiser

Veit Grunert

Michael Pfeffer

Andrea Geistanger

The disclosure concerns methods for the detection of an analyte in a sample by electro-chemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminescence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.

Branched-chain amines in electrochemiluminescence detection

An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.

Detection of anti-p53 antibodies

A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.

Circulating Angiopoietin-2 (Ang-2) for the prediction of recurrence of atrial fibrillation

The disclosure concerns methods for the detection of an analyte in a sample by electrochemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminscence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.

Herein is reported a fusion polypeptide according to formula INH&#x2014;S&#x2014;X&#x2014;S&#x2014;COOH&#x2003;&#x2003;(formula I)whereinXcomprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide,S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and&#x2014; denotes a peptide bond,wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein Xis inserted in place of the insert-in-flap-domain of the second polypeptide.

Amino acid sequence presenting fusion polypeptide and its use

Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.

Antibody specifically binding to insulin-like growth factor-1

The present invention relates to the assessment of lung cancer. It discloses the use of protein ASC in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring ASC in the sample. Measurement of ASC can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.

ASC as a marker for lung cancer

Described is a method aiding in the assessment of rheumatoid arthritis ('RA'). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, including measuring the concentration of anti-CCP and anti-PIK 3CD and correlating the concentrations determined to the absence or presence of RA. Also disclosed is the use of a marker panel including anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method. Also described is the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).

Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-PIK3CD

Herein is reported a fusion polypeptide according to formula INH&#x2014;S&#x2014;X&#x2014;S&#x2014;COOH&#x2003;&#x2003;(formula I)wherein

Herein is reported a fusion polypeptide according to formula (I): NH&#x2014;S&#x2014;X&#x2014;S&#x2014;COOH, wherein Xcomprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein Xis inserted in place of the insert-in-flap-domain of the second polypeptide.

An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein ASC in said sample in vitro.

ASC as a marker for chronic obstructive pulmonary disease (COPD)

The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.

CYBP as a marker for lung cancer

The present invention relates to the cloning and expression of foreign protein or polypeptides in bacteria, such as. In particular, this invention relates to expression tools comprising a FKBP-type peptidyl prolyl isomerase selected from the group consisting of FkpA, SlyD, and trigger factor; methods of recombinant protein expression, the recombinant polypeptides thus obtained, as well as to the use of such polypeptides.

Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides

Growing community of inventors

Penzberg, Germany

Herbert Andres